NCT06787911招募中2 期
The Efficacy and Safety of Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study
Yu Wang1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2024年7月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to evaluate the efficacy and safety of Donafenib combined with PD-1 antibody in neoadjuvant therapy of locally advanced thyroid cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily enroll and sign a written informed consent form;
- •Age>=18 years old,<=80 years old, regardless of gender;
- •Locally advanced differentiated thyroid carcinoma (DTC) diagnosed by pathological histology;
- •Locally advanced DTC is defined as meeting at least one of the criteria: surgery is expected to be difficult to complete R0/R1 resection; AJCC defined T4 stage: any size of tumor infiltrating beyond the thyroid capsule to the subcutaneous soft tissue, throat, trachea, esophagus, recurrent laryngeal nerve, tumor invades the prevertebral fascia or surrounds the carotid or mediastinal vessels.
- •Voluntarily undergo tumor biopsy/operation at enrollment and exit.
- •Have not received any anti-tumor treatment in the past;
- •According to the evaluation criteria for the efficacy of solid tumors (RECIST version 1.1), there should be at least one imaging measurable lesion. Lesions located within the radiation field of previous radiotherapy can be considered measurable if confirmed to have progressed;
- •The physical condition (PS) score of the Eastern Cancer Collaborative Group (ECOG) is 0-2 points;
- •Expected survival time>3 months;
- •Female patients with fertility (referring to those who have not undergone menopause or surgical sterilization) must have a negative serum pregnancy test result within 7 days before the study drug administration;
- •Female or male patients with fertility must take reliable contraceptive measures during the study drug use period and within 60 days after the last medication use;
- •Normal function of major organs, i.e. meeting the following criteria: Blood routine examination (no blood transfusion or G-CSF used within 14 days prior to screening): a) Hemoglobin>=90 g/L; b) Absolute neutrophil count (ANC)>=1.5 × 109/L; c) Platelet count>=80 × 109/L; Blood biochemistry test (no albumin used within 14 days prior to screening): d) Total bilirubin<=1.5 x Upper limit of normal value (ULN); e) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)<=2.5 x ULN (ALT or AST<=5 x ULN allowed for subjects with liver metastasis); f) Creatinine<=1.5 x ULN; Coagulation function: g) International standardized ratio (INR) or prothrombin time (PT)<=1.5 x ULN; h) Activated partial thromboplastin time (APTT)<=1.5 x ULN; Others: i) Urinary protein<2+(if urinary protein>=2+, 24-hour urine protein quantification can be performed, and 24-hour urine protein quantification<1.0g can be included in the group).j)Myocardial enzyme profiles were within the normal range (simple laboratory abnormalities not clinically significant were also allowed to be included)
排除标准
- •Other histological subtypes of thyroid cancer (such as undifferentiated carcinoma, myeloid carcinoma, lymphoma, or sarcoma) that are not associated with DTC;
- •Patients who undergo thyroid cancer radical surgery again;
- •Central nervous system metastasis and/or cancerous meningitis with clinical symptoms, and a history of leptomeningeal carcinoma;
- •Within the first 5 years of randomization, cancer with a different primary site or histological type from thyroid cancer, or cancer coexisting with thyroid cancer but with a different primary site or histological type, except for cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (non-invasive tumors, carcinoma in situ, and tumor invasion of the lamina propria);
- •Previous or current congenital or acquired immunodeficiency disease;
- •Active or previously documented autoimmune disease or inflammatory disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, Hypophysitis, hyperthyroidism or hypothyroidism, asthma requiring bronchodilator treatment, etc.), patients with vitiligo or asthma that has been completely resolved in childhood, without any intervention in adulthood can be included;
- •Have a history of severe mental illness in the past;
- •Suffering from diseases that affect the absorption, distribution, metabolism, or clearance of investigational drugs (such as severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.); Previous or concomitant medication/treatment:
- •Has undergone major surgery (as defined by the researcher) within 4 weeks prior to enrollment, or is expected to require major surgery during the study treatment period;
- •Have received iodine-131 ablation or other local anti-tumor treatments within the past 3 months, or plan to undergo systemic anti-tumor treatment or external irradiation or other interventional treatments during the medication period of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or have used mitomycin C within 6 weeks before receiving the investigational drug treatment). The use of levothyroxine for TSH inhibition and thyroid hormone supplementation therapy is not prohibited;
- •Previously received organ or allogenic bone marrow transplantation;
- •Previously received targeted therapy drugs targeting VEGF, including but not limited to anlotinib, apatinib, bevacizumab, etc;
- •Previously received immune therapy drugs including but not limited to anti CTLA-4, anti PD-1, anti PD-L1, anti PD-L2, anti CD
- •Therapeutic anti-tumor vaccines are not included;
- •Systemic immunosuppressive drug treatment has been used within 2 weeks before enrollment, or systemic immunosuppressive drug treatment is expected to be required during the study period, except for the following cases:
- •Intranasal, inhaled, topical or local injection (such as intra-articular injection) corticosteroids;
- •The dose does not exceed 10 mg/day of prednisone or other equivalent systemic corticosteroids;
- •Prophylactic use of corticosteroids for hypersensitivity reactions;
- •Simultaneously taking drugs that may prolong QTc and/or induce apical torsion transition ventricular tachycardia (Tdp) or affect drug metabolism;
- •The patient has a known or suspected history of allergies to donafinib or similar drugs, or a history of hypersensitivity to chimeric or humanized antibodies or fusion proteins, or allergies to excipients of the study drug;
- •Imaging shows that the tumor has invaded important blood vessels, or the investigator determines that the patient's tumor is highly likely to invade important blood vessels during treatment and cause fatal bleeding;
- •Active bleeding or abnormal coagulation function, with a tendency to bleed or undergoing thrombolysis, anticoagulation, or antiplatelet therapy;
- •Have a history of gastrointestinal bleeding within the past 4 weeks or have a clear tendency for gastrointestinal bleeding (such as known local active ulcer lesions, fecal occult blood++, if continuous fecal occult blood++, gastroscopy should be performed), or other conditions determined by the researcher that may cause gastrointestinal bleeding (such as severe gastric fundus/esophageal varices);
- •Have experienced gastrointestinal perforation, abdominal fistula, or abdominal abscess within the past 6 months;
- •Have experienced thrombosis or thromboembolic events within the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc;
- •Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting surgery within the past 6 months, congestive heart failure (New York Heart Association NYHA grade>2), poorly controlled or requiring pacemaker treatment for arrhythmia, and uncontrolled hypertension (systolic blood pressure>=140 mmHg and/or diastolic blood pressure>=90 mmHg);
- •Active infections, including: a) AIDS virus (HIV/2 antibody) positive; b) Active hepatitis B (HBsAg positive and abnormal liver function); c) Active hepatitis C (HCV antibody positive or HCV RNA ≥ 103 copies/ml with abnormal liver function); d) Active tuberculosis; e) Other uncontrollable active infections (CTCAE V5.0>level 2);
- •Other significant clinical and laboratory abnormalities, which the researchers believe affect the safety evaluation, such as uncontrollable diabetes, chronic kidney disease, peripheral neuropathy of grade II or above (CTCAE V5.0), thyroid dysfunction, etc;
- •Has not yet recovered from surgery, such as the presence of unhealed incisions or serious postoperative complications;
- •Within 4 weeks prior to enrollment or possibly during the study period, receive any attenuated live vaccines;
- •Pregnant or lactating women, as well as female or male patients with fertility who are unwilling or unable to take effective contraceptive measures;
- •Have a history of alcohol, psychotropic drugs, or other substance abuse within the past 6 months;
- •Have received clinical trials of other drugs or medical devices within 4 weeks prior to enrollment. TSH inhibition therapy is not prohibited;
- •Unable to follow the research protocol for treatment or follow up on schedule;
- •Any other researcher deemed ineligible for enrollment.
研究组 & 干预措施
Treatment group
Experimental
Patients receive Donafenib and PD-1 antibody Sintilimab
干预措施: Donafeib with Sintilimab (Drug)
结局指标
主要结局
Objective response rate
时间窗: From enrollment to the end of treatment at 4 weeks
The proportion of patients with complete response (CR) and partial response (PR) to the total number of evaluable cases.
次要结局
- R0/R1 resection rate(From enrollment to the end of treatment at 4 weeks)
- Progression free survival(5 years after surgery)
- Tumor recurrence time(5 years after surgery)
- disease control rate(5 years after surgery)
- 3-year local recurrence-free survival(From enrollment to the end of treatment at 3 years)
- 5-year local recurrence-free survival(From enrollment to the end of treatment at 5 years)
研究者
Yu Wang
Professor
Fudan University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabHepatocellular CarcinomaNCT06498622Anhui Provincial Hospital45
终止
1 期
A Study of Donafenib Monotherapy in Advanced Oesophageal CancerOesophageal CancerNCT02489201Suzhou Zelgen Biopharmaceuticals Co.,Ltd19
尚未招募
4 期
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyUnresectable Hepatocellular CarcinomaNCT06496815Tongji Hospital32
已完成
2 期
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCarcinoma, Non-Small-Cell LungNCT04452877Novartis Pharmaceuticals40
已完成
2 期
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid CancerDifferentiated Thyroid CancerNCT02870569Suzhou Zelgen Biopharmaceuticals Co.,Ltd48